The multikinase inhibitor sorafenib also activates the upstream kinase MKK4 and subsequently leads to JNK phosphorylation; and which is used to treat liver, kidney, and thyroid cancer [64]. The gene discussed is MAP2K4; the disease is thyroid gland carcinoma.